Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer

PURPOSE: Despite positive responses in phase II clinical trials, the bioreductive prodrug apaziquone failed to achieve statistically significant activity in non-muscle invasive bladder cancer in phase III trials. Apaziquone was administered shortly after transurethral resection and here we test the...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Roger M., Loadman, Paul M., Reddy, Guru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499894/
https://www.ncbi.nlm.nih.gov/pubmed/30868237
http://dx.doi.org/10.1007/s00280-019-03812-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499894/
https://www.ncbi.nlm.nih.gov/pubmed/30868237
http://dx.doi.org/10.1007/s00280-019-03812-7

Ejemplares similares